India's Dr.Reddy's ends study of COVID-19 drug Avigan in Kuwait
Data from the Kuwait trial, conducted in partnership with United Arab Emirates-based medical alliance Global Response Aid FZCO (GRA), showed that the difference in time taken by Avigan and placebo to resolve a sustained absence of oxygen in the tissues was not significant enough to continue the trial.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | COVID-19 | India Health | Kuwait Health | Middle East Health | Partnerships | Pharmaceuticals | Study | UAE Health